Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2019 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Depreciation & Amortization (CF) of $238000.0 in Q1 2026, down 69.09% quarter-over-quarter from $770000.0 in Q4 2025, and down 71.22% on a YoY basis from $827000.0 in Q1 2025.
Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $238000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 71.22% year-over-year to $238000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 9.07% YoY), while the FY2025 annual figure was $3.3 million, up 5.77% from the prior year.
- Depreciation & Amortization (CF) was $238000.0 for Q1 2026 at Foghorn Therapeutics, down from $770000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $900000.0 in Q3 2022 to a low of $238000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $796705.9 across 5 years, with a median of $800000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) grew 28.57% in 2025, then tumbled 71.22% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $848000.0 in 2022, then advanced by 6.13% to $900000.0 in 2023, then slipped by 15.44% to $761000.0 in 2024, then grew by 1.18% to $770000.0 in 2025, then tumbled by 69.09% to $238000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $238000.0 (Q1 2026), $770000.0 (Q4 2025), and $900000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | 238,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 770,000.00 |
| Dec 31, 2025 | 770,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 827,000.00 |
| Mar 31, 2025 | 827,000.00 |
| Dec 31, 2024 | 761,000.00 |
| Dec 31, 2024 | 761,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |